อ้างอิง ของ สแตติน

  1. ↑ Istvan ES and Deisenhofer J (2001). "Structural mechanism for statin inhibition of HMG-CoA reductase". Science. 292 (5519): 1160-1164. doi:10.1126/science.1059344. PMID 11349148.
  2. 1 2 Friesen JA and Rodwell VW (2004). "The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases" (PDF). Genome Biol. 5 (11): 248. doi:10.1186/gb-2004-5-11-248.
  3. 1 2 3 4 Gullo V and Demain AL (2003). Statins Fermentation Products for Cholesterol Control in Humans. CRC Press. p. 435-42. ISBN 9781439891674. Unknown parameter |in= ignored (help)
  4. 1 2 3 Banach M, Filipiak KJ, and Opolski G (2013). Aktualny stan wiedzy na temat statyn. Poznań. p. 384-385. ISBN 978-83-63622-21-3.CS1 maint: multiple names: authors list (link)
  5. 1 2 Gunde-Cimerman N and Cimerman A (1995). "Pleurotus Fruiting Bodies Contain the Inhibitor of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase—Lovastatin". Experimental Mycologyl. 19 (1): 1-6. doi:10.1006/emyc.1995.1001. PMID 7614366.
  6. 1 2 Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, and Fønnebø V (2006). "Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials" (PDF). Chinese Medicinel. 1 (4): 1-13. doi:10.1186/1749-8546-1-4.CS1 maint: multiple names: authors list (link)
  7. 1 2 U.S. Food and Drug Administration (2007). "FDA Warns Consumers to Avoid Red Yeast Rice Products Promoted on Internet as Treatments for High Cholesterol Products found to contain unauthorized drug". สืบค้นเมื่อ February 2, 2016.
  8. 1 2 Official Journal of the European Union (March 6, 2014). "ROZPORZĄDZENIE KOMISJI (UE) NR 212/2014 z dnia 6 marca 2014 r. zmieniające rozporządzenie (WE) nr 1881/2006 w odniesieniu do najwyższych dopuszczalnych poziomów zanieczyszczenia „cytrynina" w suplementach diety na bazie ryżu poddanego fermentacji grzybami Monascus purpureus". สืบค้นเมื่อ February 2, 2016.
  9. 1 2 OSOZ. "ArmoLipid". สืบค้นเมื่อ February 2, 2016.
  10. ↑ Marian Gapiński, Wanda Woźniak, Mirosława Ziombra (1992). Boczniak. Poznań, Poland: Państwowe Wydawnictwo Rolnicze i Leśne. p. 7-10. ISBN 83-09-01572-0.CS1 maint: multiple names: authors list (link)
  11. ↑ Apteka Stlonik (July 29, 2014). "Armolipid tabletki na cholesterol 20tabletek". สืบค้นเมื่อ February 6, 2016.
  12. ↑ Medycyna Praktyczna (July 29, 2014). "Rola monakoliny w farmakoterapii dyslipidemii". สืบค้นเมื่อ February 6, 2016.
  13. ↑ Frost & Sullivan Market Insight (June 22, 2000). "Japanese Antihyperlipidemic Market: New Statin Products and Their Marketing Strategies". สืบค้นเมื่อ February 6, 2016.
  14. 1 2 Mukhtar RY, Reid J, and Reckless JP (2005). "Pitavastatin". Int J Clin Pract. 59 (2). doi:10.1111/j.1742-1241.2005.00461.x. PMID 15854203.CS1 maint: multiple names: authors list (link)
  15. 1 2 Hanke H, Lenz C, and Finking G (2001). "The discovery of the pathophysiological aspects of atherosclerosis--a review". Acta Chir Belg. 101 (4): 162-9. PMID 11680058.CS1 maint: multiple names: authors list (link)
  16. 1 2 Izabela Sokoluk. Rola statyn w zapobieganiu i leczeniu chorób układu krążenia. Medycyna Rodzinna. p. 219-26. ISSN 1731-2523. สืบค้นเมื่อ February 6, 2016.
  17. ↑ Parry CH (1799). An inquiry into the symptoms and causes of the syncope anginosa, commonly called angina pectoris : illustrated by dissections. London: Printed by R. Cruttwell and sold by Cadell and Davies. p. 1755-822.
  18. ↑ Fay Bound Alberti (2008). "Angina Pectoris and the Arnolds: Emotions and Heart Disease in the Nineteenth Century" (PDF). Medical History. 52 (2). PMC 2329859. PMID 18458783. สืบค้นเมื่อ February 6, 2016.
  19. ↑ Barbara Dąbrowska (1997). Podręczny słownik medyczny łacińsko-polski i polsko-łaciński. Warszawa, Polnad: PZWL. p. 54. ISBN 83-200-2109-X.
  20. ↑ Barbara Dąbrowska (1997). Podręczny słownik medyczny łacińsko-polski i polsko-łaciński. Warszawa, Polnad: PZWL. p. 60. ISBN 83-200-2109-X.
  21. ↑ Renu Virmani, Jagat Narula, Martin B. Leon, James T. Willerson (2008). The Vulnerable Atherosclerotic Plaque: Strategies for Diagnosis and Management. Wiley-Blackwell. p. 6. ISBN 9780470987339.CS1 maint: multiple names: authors list (link)
  22. ↑ World Health Organization (June 4, 2014). "Milestones in knowledge of heart and vascular disorders" (PDF). สืบค้นเมื่อ February 6, 2016.
  23. 1 2 3 Daniel Steinberg (2004). "Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy: part I". The Journal of Lipid Research. 45: 1583-93. doi:10.1194/jlr.R400003-JLR200. สืบค้นเมื่อ February 6, 2016.
  24. ↑ Endo A (2010). "A historical perspective on the discovery of statins". Proc Jpn Acad Ser B Phys Biol Sci. 86 (5): 484-93. doi:10.2183/pjab.86.484. PMC 3108295. PMID 20467214.
  25. ↑ Maciej Banach, Jacek Rysz, Krzysztof J. Filipiak (2009). Simwastatyna. Gdańsk, Poland: Via Medica. p. 2. ISBN 9788375991185.CS1 maint: multiple names: authors list (link)
  26. ↑ Tadeusz Fojt, Jan Duława, Andrzej Kurek, Mirosława Janowska i inni (2002). "Czynniki ryzyka chorób układu sercowo--naczyniowego u chorych na nadciśnienie tętnicze i cukrzycę w bardzo zaawansowanym wieku". Diabetologia Doświadczalna i Kliniczna. 2 (4): 303-7. ISSN 1643-3165.CS1 maint: multiple names: authors list (link)
  27. ↑ Kannel WB, Dawber TR, Kagan A, and Revotskie N (1961). "Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study". Ann Intern Med. 55 (1): 33-50. PMID 13751193.CS1 maint: multiple names: authors list (link)
  28. 1 2 Akira Endo (1992). "The discovery and development of HMG-CoA reductase inhibitors" (PDF). Journal of Lipid Research. 33 (11): 1569-82. PMID 15531278.
  29. ↑ J. McMichael (1979). "Fats and atheroma: an inquest" (PDF). Br Med J. 1 (6157): 173-5. PMC 1597573. PMID 105776. สืบค้นเมื่อ February 6, 2016.
  30. ↑ DJ Gordon, J Knoke, JL Probstfield, R Superko, and HA Tyroler (1986). "High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial". Circulation. 74: 1217-25. doi:10.1161/01.CIR.74.6.1217. สืบค้นเมื่อ February 6, 2016.CS1 maint: multiple names: authors list (link)
  31. ↑ Endo, Akira; Kuroda M.; Tsujita Y. (December 1976). "ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium". Journal of Antibiotics (Tokyo). 29 (12): 1346–8. doi:10.7164/antibiotics.29.1346. PMID 1010803.
  32. ↑ Brown, Allan G.; Smale, Terry C.; King, Trevor J.; Hasenkamp, Rainer; Thompson, Ronald H. (1976). "Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum". J. Chem. Soc., Perkin Trans. 1 (11): 1165–1170. doi:10.1039/P19760001165. PMID 945291.
  33. 1 2 Marcin Bizukojć, Stanisław Ledakowicz (2005). "Biosynteza lowastatyny przez Aspergillus terreus" (PDF). Biotechnologia – monografie (in German). 2 (2): 55-67.CS1 maint: unrecognized language (link)
  34. 1 2 Akira Endo (2004). "The origin of the statins". Atherosclerosis Supplements. 5 (3): 125-30. doi:10.1016/j.atherosclerosissup.2004.08.033. PMID 15531285.
  35. ↑ United States Patent Office. (November 9, 1980). "Hypocholesteremic fermentation products and process of preparation US 4231938 A". สืบค้นเมื่อ February 6, 2016.
  36. ↑ Y. Kishida, A. Naito, S. Iwado, A. Terahara (1991). "Research and development of pravastatin". Yakugaku Zasshi (in Japanese). 111 (9): 469-87. PMID 1762049.CS1 maint: multiple names: authors list (link) CS1 maint: unrecognized language (link)
  37. ↑ Daiichi Sankyo (February 17, 2006). "Future Business Prospects of the Hyperlipidemia Drug Pravastatin in the United States". สืบค้นเมื่อ February 6, 2016.
  38. ↑ Returns on Pharmaceutical R&D. W. Pharmaceutical R&D: Costs, Risks, and Rewards. Washington, DC: U.S. Congress, Office of Technology Assessment. p. 74. ISBN 0160416582.
  39. 1 2 3 Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski (2013). Aktualny stan wiedzy na temat statyn. Poznań, Poland. ISBN 9788363622213.CS1 maint: multiple names: authors list (link)
  40. ↑ Medycyna Praktyczna (August 9, 2001). "Ceriwastatyna wycofana z obrotu".
  41. 1 2 "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)". Lancet. 344 (8934): 1383-9. 1994. PMID 7968073.
  42. 1 2 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998). "Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels". N Engl J Med. 339 (19): 1349-57. doi:10.1056/NEJM199811053391902. PMID 9841303.
  43. 1 2 F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau; และคณะ (1996). "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators". N Engl J Med. 335 (14): 1001-9. doi:10.1056/NEJM199610033351401. PMID 8801446. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  44. 1 2 J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles; และคณะ (1995). "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group". N Engl J Med. 333 (20): 1301-7. doi:10.1056/NEJM199511163332001. PMID 7566020. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  45. 1 2 J.R. Downs, M. Clearfield, S. Weis, E. Whitney; และคณะ (1998). "Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study". JAMA. 279 (20): 1615-22. doi:10.1001/jama.279.20.1615. PMID 9613910. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  46. 1 2 R. Collins, J. Armitage, S. Parish, P. Sleight; และคณะ (2004). "Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions". Lancet. 363 (9411): 757-67. doi:10.1016/S0140-6736(04)15690-0. PMID 15016485. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  47. 1 2 3 4 P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest; และคณะ (2008). "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein". N Engl J Med. 359 (21): 2195-207. doi:10.1056/NEJMoa0807646. PMID 18997196. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  48. 1 2 3 4 H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse; และคณะ (2010). "Effects of combination lipid therapy in type 2 diabetes mellitus". N Engl J Med. 362 (17): 1563-74. doi:10.1056/NEJMoa1001282. PMID 20228404. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  49. 1 2 3 4 C. Baigent, M.J. Landray, C. Reith, J. Emberson; และคณะ (2011). "The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial". Lancet. 377 (9784): 2181-92. doi:10.1016/S0140-6736(11)60739-3. PMID 21663949. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  50. ↑ Michael B. Bottorff (November 01, 2004). "Safety and Statins: Pharmacologic and Clinical Perspectives - See more at: http://www.ajmc.com/journals/supplement/2004/2004-11-vol10-n3PreventiveMedicine/Nov04-1971pS030-S037#sthash.VZLloQYR.dpuf". สืบค้นเมื่อ February 6, 2016. Check date values in: |date= (help); External link in |title= (help)
  51. 1 2 Alfred Zejc, and Maria Gorczyca (2008). Chemia leków. Warszawa, Poland: PZWL. p. 418-21. ISBN 9788320036527.
  52. ↑ P. Alagona (2010). "Pitavastatin: evidence for its place in treatment of hypercholesterolemia". Core Evid. 5: 91-105. doi:10.2147/CE.S8008. PMID 21468365.
  53. ↑ Dieter Steinhilber, Manfred Schubert-Zsilavecz, Hermann J. Roth (2012). "Chemia Medyczna". MedPharm Polska: 437. ISBN 9788362283941. Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link)
  54. ↑ Dieter Steinhilber, Manfred Schubert-Zsilavecz, Hermann J. Roth (2012). "Chemia Medyczna". MedPharm Polska: 438. ISBN 9788362283941. Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link)
  55. ↑ Kathleen Botham, Peter A. Mayes (2006). Synteza, transport i wydalanie cholesterolu. Warszawa, Poland: Wydawnictwo Lekarskie PZWL. p. 283. ISBN 9788320035735. Unknown parameter |in= ignored (help)
  56. ↑ Wojciech Kostowski (2003). Leki a lipidy krwi. Farmakoterapia miażdżycy. Warszawa, Poland: PZWL. p. 220. ISBN 8320033519. Unknown parameter |in= ignored (help)
  57. 1 2 Ernst Mutschler, Gerd Geisslinger, Heyo Kroemer, Peter Ruth, Monika Schäfer-Korting (2010). Farmakologia i toksykologia. Wrocław, poland: MedPharm polska. p. 554-61. ISBN 9788360466810.CS1 maint: multiple names: authors list (link)
  58. 1 2 V (2009). Simwastatyna. Gdańsk, Poland: Via Medica. p. 5-6. ISBN 9788375991185.
  59. ↑ Dieter Steinhilber, Manfred Schubert-Zsilavecz, Hermann J. Roth (2012). Chemia Medyczna. MedPharm Polska. p. 63. ISBN 9788362283941.CS1 maint: multiple names: authors list (link)
  60. ↑ J. Davignon (2012). "Pleiotropic effects of pitavastatin". Br J Clin Pharmacol. 73 (4): 518-35. doi:10.1111/j.1365-2125.2011.04139.x. PMID 22053916.
  61. ↑ B. Sadowitz, K.G. Maier, V. Gahtan (2010). "Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease". Vasc Endovascular Surg. 44 (4): 241-51. doi:10.1177/1538574410362922. PMID 20403949.CS1 maint: multiple names: authors list (link)
  62. ↑ J. Kiyan, A. Kusch, S. Tkachuk, J. Krämer; และคณะ (2007). "Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor". Atherosclerosis. 195 (2): 254-61. doi:10.1016/j.atherosclerosis.2006.12.030. PMID 17275828. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  63. ↑ Marcin Barylski, Andrzej Tynkarski (2010). Rpsuwastatyna. Gdańsk, Polnad: Via Medica. p. 17-8. ISBN 9788375993066.
  64. ↑ Maciej Banach, Jacek Rysz, Krzysztof J. Filipiak (2009). Simwastatyna. Gdańsk, Polnad: Via Medica. p. 12-4. ISBN 9788375991185.CS1 maint: multiple names: authors list (link)
  65. ↑ C.D. Furberg, B. Pitt (2001). "Withdrawal of cerivastatin from the world market" (PDF). Curr Control Trials Cardiovasc Med. 2 (5): 205-7. PMC 59524. PMID 11806796.
  66. ↑ Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski. Aktualny stan wiedzy na temat statyn. Poznań, Poland. p. 115. ISBN 9788363622213.CS1 maint: multiple names: authors list (link)
  67. ↑ Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski. Aktualny stan wiedzy na temat statyn. Poznań, Poland. p. 32. ISBN 9788363622213.CS1 maint: multiple names: authors list (link)
  68. ↑ S. Thom, N. Poulter, J. Field, A. Patel; และคณะ (2013). "Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial". JAMA. 310 (9): 918-29. doi:10.1001/jama.2013.277064. PMID 24002278. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  69. ↑ U.S. Food and Drug Administration. "Drugs@FDA FDA Approved Drug Products". สืบค้นเมื่อ February 7, 2016.
  70. ↑ European Medicines Agency. "Human medicines: regulatory information". สืบค้นเมื่อ February 7, 2016.
  71. ↑ WHO Collaborating Centre for Drug Statistics Methodology. "WHOCC – ATC/DDD Index (sekcja: C10)". Norwegian Institute of Public Health. สืบค้นเมื่อ February 7, 2016.
  72. ↑ G. Sanz, V. Fuster (2013). "Prevention: Polypills for cardiovascular prevention: a step forward?". Nat Rev Cardiol. 10 (12): 683-4. doi:10.1038/nrcardio.2013.157. PMID 24101102.
  73. 1 2 Drug Bank. "Atorvastatin DB01076 (APRD00055)". สืบค้นเมื่อ February 7, 2016.
  74. ↑ Drug Bank. "Cerivastatin DB00439 (APRD00102)". สืบค้นเมื่อ February 7, 2016.
  75. ↑ Drug Bank. "Fluvastatin DB01095 (APRD00346)". สืบค้นเมื่อ February 7, 2016.
  76. ↑ Drug Bank. "Lovastatin DB00227 (APRD00370)". สืบค้นเมื่อ February 7, 2016.
  77. 1 2 Drug Bank. "Pitavastatin DB08860 (APRD06514)". สืบค้นเมื่อ February 7, 2016.
  78. ↑ Drug Bank. "Pravastatin DB00175 (APRD00328)". สืบค้นเมื่อ February 7, 2016.
  79. ↑ Drug Bank. "Rosuvastatin DB01098 (APRD00546)". สืบค้นเมื่อ February 7, 2016.
  80. 1 2 Drug Bank. "Simvastatin DB00641 (APRD00104)". สืบค้นเมื่อ February 7, 2016.
  81. ↑ Farmakopea Polska wydanie IX. T. 1. (2011). Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych. Warszawa, Poland. p. 1661-4. ISBN 9788388157783.
  82. ↑ U.S. Food and Drug Administration (2001). "BAYCOL®(cerivastatin sodium tablets)" (PDF). สืบค้นเมื่อ February 7, 2016.
  83. ↑ Farmakopea Polska wydanie IX. T. 2. (2011). Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych. Warszawa, Poland. p. 1661-4. ISBN 9788388157790.
  84. ↑ Farmakopea Polska wydanie IX. T. 2. (2011). Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych. Warszawa, Poland. p. 1661-4. ISBN 9788388157790.
  85. ↑ U.S. Food and Drug Administration (2013). "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LIVALO® safely and effectively. See full prescribing information for LIVALO. LIVALO (pitavastatin) Tablet, Film Coated for Oral use Initial U.S. Approval: 2009" (PDF). สืบค้นเมื่อ February 7, 2016. line feed character in |title= at position 38 (help)
  86. ↑ Farmakopea Polska wydanie IX. T. 2. (2011). Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych. Warszawa, Poland. p. 1661-4. ISBN 9788388157790.
  87. ↑ U.S. Food and Drug Administration (2014). "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CRESTOR safely and effectively. See full prescribing information for CRESTOR. CRESTOR (rosuvastatin calcium) tablets Initial U.S. Approval: 2003" (PDF). สืบค้นเมื่อ February 7, 2016. line feed character in |title= at position 38 (help)
  88. ↑ Farmakopea Polska wydanie IX. T. 2. (2011). Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych. Warszawa, Poland. p. 1661-4. ISBN 9788388157790.
  89. ↑ Santa Cruz Biotechnology. "Cerivastatin, Sodium Salt (CAS 143201-11-0)". สืบค้นเมื่อ February 7, 2016.
  90. ↑ Santa Cruz Biotechnology. "Pitavastatin Lactone (CAS 141750-63-2)". สืบค้นเมื่อ February 7, 2016.
  91. ↑ Santa Cruz Biotechnology. "Rosuvastatin Calcium Salt (CAS 147098-20-2)". สืบค้นเมื่อ February 7, 2016.
  92. 1 2 3 4 5 U.S. Drug and Food Administration (October, 2012). "HIGHLIGHTS OF PRESCRIBING INFORMATION: These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR" (PDF). สืบค้นเมื่อ February 4, 2016. Check date values in: |date= (help)
  93. 1 2 3 4 5 U.S. Drug and Food Administration. "BAYCOL® (cerivastatin sodium tablets)" (PDF). สืบค้นเมื่อ February 4, 2016. line feed character in |title= at position 19 (help)
  94. 1 2 3 4 5 U.S. Drug and Food Administration (October, 2012). "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Lescol®/Lescol® XL safely and effectively. See full prescribing information for Lescol®/ Lescol® XL. Lescol® (fluvastatin sodium) capsules/ Lescol® XL (fluvastatin sodium) extended-release tablets for oral use. Initial U.S. Approval: 1993/ 2000" (PDF). สืบค้นเมื่อ February 4, 2016. line feed character in |title= at position 38 (help); Check date values in: |date= (help)
  95. 1 2 3 4 5 U.S. Drug and Food Administration. "TABLETS MEVACOR® (LOVASTATIN)" (PDF). สืบค้นเมื่อ February 4, 2016.
  96. 1 2 3 4 5 U.S. Drug and Food Administration. "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LIVALO® safely and effectively. See full prescribing information for LIVALO. LIVALO (pitavastatin) Tabl" (PDF). สืบค้นเมื่อ February 4, 2016. line feed character in |title= at position 38 (help)
  97. 1 2 3 4 5 U.S. Drug and Food Administration. "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRAVACHOL safely and effectively. See full prescribing information for PRAVACHOL. PRAVACHOL (pravastatin sodium) Tablets Initial U.S. Approval: 1991" (PDF). สืบค้นเมื่อ February 4, 2016. line feed character in |title= at position 38 (help)
  98. 1 2 3 4 5 U.S. Drug and Food Administration (July, 2014). "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CRESTOR safely and effectively. See full prescribing information for CRESTOR. CRESTOR (rosuvastatin calcium) tablets Initial U.S. Approval: 2003" (PDF). สืบค้นเมื่อ February 4, 2016. line feed character in |title= at position 38 (help); Check date values in: |date= (help)
  99. 1 2 3 4 5 Maciej Banach, Jacek Rysz, Krzysztof J. Filipiak (2009). Simwastatyna. Gdańsk, Germany: Via Medica. p. 10. ISBN 9788375991185.CS1 maint: multiple names: authors list (link)
  100. ↑ Jadwiga Mielcarek, M. Naskrent, P. Grobelny (2009). "Photochemical properties of simvastatin and lovastatin induced by radiation". Journal of Thermal Analysis and Calorimetry. 96 (1): 301-5. doi:10.1007/s10973-008-9322-6. PMID 13886150.CS1 maint: multiple names: authors list (link)
  101. 1 2 3 4 5 6 Piecha, Małgorzata, Sarakha, Mohamed, Trebse, Polonca, Kocar, Drago (2010). "Stability studies of cholesterol lowering statin drugs in aqueous samples using HPLC and LC-MS". Environ Chem Lett. 2 (2): 185-91. doi:10.1007/s10311-009-0207-0.CS1 maint: multiple names: authors list (link)
  102. ↑ A. Barra Caracciolo, E. Topp, P. Grenni (2014). "Pharmaceuticals in the environment: Biodegradation and effects on natural microbial communities. A review". J Pharm Biomed Anal. 106: 25-36. doi:10.1016/j.jpba.2014.11.040. PMID 25534003.CS1 maint: multiple names: authors list (link)
  103. ↑ Piecha, Małgorzata, Sarakha, Mohamed, Trebse, Polonca (2010). "Photocatalytic degradation of cholesterol-lowering statin drugs by TiO2-based catalyst. Kinetics, analytical studies and toxicity evaluation". Journal of Photochemistry and Photobiology A: Chemistry. 213 (1): 61-69. doi:10.1016/j.jphotochem.2010.04.020.CS1 maint: multiple names: authors list (link)
  104. ↑ Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG (2003). "Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals". Am. J. Cardiol. 91 (5A): 11C–17C, discussion 17C–19C. doi:10.1016/S0002-9149(03)00004-3. PMID 12646338.CS1 maint: multiple names: authors list (link)
  105. ↑ Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski (2013). Aktualny stan wiedzy na temat statyn. Poznań, Poland. p. 33. ISBN 9788363622213.CS1 maint: multiple names: authors list (link)
  106. 1 2 3 Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski (2013). Aktualny stan wiedzy na temat statyn. Poznań, Poland. p. 35. ISBN 9788363622213.CS1 maint: multiple names: authors list (link)
  107. ↑ M.P. Vaquero, F.J. Sánchez Muniz, S. Jiménez Redondo, P. Prats Oliván; และคณะ (2010). "Major diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins". Nutr Hosp. 25 (2): 193-206. PMID 20449528. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  108. ↑ I. Ieiri, S. Suwannakul, K. Maeda, H. Uchimaru; และคณะ (2007). "SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers". Clin Pharmacol Ther. 85 (2): 541-7. doi:10.1038/sj.clpt.6100190. PMID 17460607. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  109. ↑ W.J. Hua, W.X. Hua, H.J. Fang (2012). "The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins" (PDF). Cardiovasc Ther. 30 (5): e234-41. doi:10.1111/j.1755-5922.2011.00290.x. PMID 21884024.CS1 maint: multiple names: authors list (link)
  110. 1 2 3 M. Hu, V.W.L. Mak, T.T.W. Chu, M.M.Y. Waye, B. Tomlinson (2009). "Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease Current Pharmacogenomics and Personalized Medicine". Current Pharmacogenomics and Personalized Medicine. 7 (1): 1-26. doi:10.2174/187569209787582349.CS1 maint: multiple names: authors list (link)
  111. ↑ M. Whirl-Carrillo, E.M. McDonagh, J.M. Hebert, L. Gong; และคณะ (2012). "Pharmacogenomics knowledge for personalized medicine" (PDF). Clin Pharmacol Ther. 92 (4): 414-417. doi:10.1038/clpt.2012.96. PMC 3660037. PMID 22992668. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  112. ↑ PharmGKB Pharmacogenomics. Knowledge. Implementation. "Pravastatin Pathway, Pharmacokinetics". สืบค้นเมื่อ February 11, 2016.
  113. 1 2 P.J. Neuvonen, M. Niemi, J.T. Backman. "Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance". Clin Pharmacol Ther. 80 (6): 565-81. doi:10.1016/j.clpt.2006.09.003. PMID 17178259.CS1 maint: multiple names: authors list (link)
  114. ↑ K.A. Kellick, M. Bottorff, P.P. Toth, The National Lipid Association’s Safety Task Force. (2014). "A clinician's guide to statin drug-drug interactions". J Clin Lipidol. 8 (suppl 3): S30-46. doi:10.1016/j.jacl.2014.02.010. PMID 24793440.CS1 maint: multiple names: authors list (link)
  115. 1 2 3 4 Medycyna Praktyczna. "Crestor". สืบค้นเมื่อ February 12, 2016.
  116. ↑ Tomasz Pasierski (2002). "Pierwotna i wtórna prewencja choroby wieńcowej". สืบค้นเมื่อ February 12, 2016.
  117. ↑ Marcin Wełnicki, Artur Mamcarz (2013). Mała encyklopedia statyn. Medical Education. p. 21. ISBN 9788362510702.
  118. 1 2 3 4 Medycyna Praktyczna (February 13, 2016). "Zocor".
  119. 1 2 3 4 Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (February 13, 2016). "Zocor" (PDF).
  120. 1 2 3 4 Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (February 13, 2016). "Roswera" (PDF).
  121. 1 2 3 4 Medycyna Praktyczna (February 13, 2016). "Prawator".
  122. 1 2 3 Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (February 13, 2016). "Roswera" (PDF).
  123. ↑ Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (February 13, 2016). "Livazo" (PDF).
  124. 1 2 3 Medycyna Praktyczna (February 13, 2016). "Lescol".
  125. ↑ Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (February 13, 2016). "Lescol" (PDF).
  126. ↑ Medycyna Praktyczna (February 13, 2016). "Lovasteroll".
  127. 1 2 Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (February 13, 2016). "Lovasteroll" (PDF).
  128. 1 2 3 Medycyna Praktyczna (February 13, 2016). "Sortis".
  129. 1 2 Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (February 13, 2016). "Atorsteroll" (PDF).
  130. ↑ Wiktoria Leśniak, Piotr Gajewski (2012). "Prewencja chorób sercowo-naczyniowych w praktyce klinicznej. Podsumowanie wytycznych europejskich 2012". European Heart Journal. 33: 1635-701.
  131. 1 2 Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski (2013). Aktualny stan wiedzy na temat statyn. Poznań, poland. p. 178. ISBN 9788363622213.CS1 maint: multiple names: authors list (link)
  132. ↑ European Society of Cardiology. "SCORE Risk Charts:The European cardiovascular disease risk assessment model". สืบค้นเมื่อ February 13, 2016.
  133. ↑ Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski. Aktualny stan wiedzy na temat statyn. Poznań, Poland. p. 179. ISBN 9788363622213.CS1 maint: multiple names: authors list (link)
  134. ↑ Barbara Cybulska, Longina Kłosiewicz-Latoszek (2014). "Podejście do leczenia hipolipemizującego w świetle aktualnych wytycznych amerykańskich i europejskich". Medycyna Praktyczna. 275 (1): 18-22.
  135. ↑ P. Hadji, S. Klein, H. Gothe, B. Häussler; และคณะ (2013). "The epidemiology of osteoporosis – Bone Evaluation Study (BEST): an analysis of routine health insurance data". Dtsch Arztebl Int. 10 (4): 52-7. doi:10.3238/arztebl.2013.0052. PMID 23413388. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  136. ↑ Piotr Głuszko, Witold Tłustochowicz, Mariusz Korkosz: Choroby metaboliczne. W (2014). Choroby wewnętrzne. Andrzej Szczeklik (red.). Kraków, Poland: Wydawnictwo Medycyna Praktyczna. p. 1936. ISBN 9788374304047.CS1 maint: multiple names: authors list (link)
  137. ↑ Zofia Guła, Mariusz Korkosz (2010). "Osteoporoza w wieku podeszłym – patogeneza, ocena ryzyka złamań i skuteczność przeciwzłamaniowa leków". Gerontologia Polska. 18 (3): 107-13.
  138. ↑ Grzegorz Goncerz (July, 2013). "Diagnostyka i leczenie w osteoporozie - wytyczne 2013". สืบค้นเมื่อ February 13, 2016. Check date values in: |date= (help)
  139. 1 2 3 Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski (2013). Aktualny stan wiedzy na temat statyn. Poznań, Poland. p. 383. ISBN 9788363622213.CS1 maint: multiple names: authors list (link)
  140. 1 2 S.B. Jadhav, G.K. Jain (2006). "Statins and osteoporosis: new role for old drugs". J Pharm Pharmacol. 58 (1): 3-18. doi:10.1211/jpp.58.1.0002. PMID 16393459. สืบค้นเมื่อ February 13, 2016.
  141. 1 2 A.N. Tsartsalis, C. Dokos, G.D. Kaiafa, D.N. Tsartsalis; และคณะ (2012). "Statins, bone formation and osteoporosis: hope or hype?". Hormones (Athens). 12 (1): 126-39. PMID 22801558. สืบค้นเมื่อ February 13, 2016. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  142. ↑ Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski (2013). Aktualny stan wiedzy na temat statyn. Poznań, Poland. p. 385. ISBN 9788363622213. |access-date= requires |url= (help)CS1 maint: multiple names: authors list (link)
  143. 1 2 Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski (2013). Aktualny stan wiedzy na temat statyn. Poznań, Poland. p. 384. ISBN 9788363622213. |access-date= requires |url= (help)CS1 maint: multiple names: authors list (link)
  144. ↑ J.K. Liao (2004). "Statin therapy: having the good without the bad" (PDF). Hypertension. 43 (6): 1171-2. doi:10.1161/01.HYP.0000126153.80112.5c. PMC 2640840. PMID 15166178. สืบค้นเมื่อ February 13, 2016.
  145. ↑ M.L. Barreto, M.G. Teixeira, E.H. Carmo. (2006). "Infectious diseases epidemiology". J Epidemiol Community Health (in อังกฤษ). 60 (3): 192-5. doi:10.1136/jech.2003.011593. PMID 16476746. สืบค้นเมื่อ February 13, 2016.CS1 maint: multiple names: authors list (link)
  146. 1 2 Iwata A, Shirai R, Ishii H, Kushima H, Otani S, Hashinaga K, Umeki K, Kishi K, Tokimatsu I, Hiramatsu K, Kadota J. (2012). "Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells". Clin Exp Immunol. 168 (2): 234-40. doi:10.1111/j.1365-2249.2012.04564.x. PMC 3390525. PMID 22471285. สืบค้นเมื่อ February 13, 2016.CS1 maint: multiple names: authors list (link)
  147. 1 2 3 4 Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski (2013). Aktualny stan wiedzy na temat statyn. Poznań, Poland. p. 386. ISBN 9788363622213.CS1 maint: multiple names: authors list (link)
  148. ↑ Jan Kuś (2014). Choroby wewnętrzne. Kraków, Poland: Wydawnictwo Medycyna Praktyczna. p. 686. ISBN 9788374304047. Unknown parameter |in= ignored (help); |access-date= requires |url= (help)
  149. 1 2 Władysław Pierzchała, Ewa Niżankowska-Mogilnicka, Filip Mejza (2014). Przewlekła obturacyjna choroba płuc. Kraków, Poland: Wydawnictwo Medycyna Praktyczna. p. 2258. ISBN 9788374304047. Unknown parameter |in= ignored (help); |access-date= requires |url= (help)CS1 maint: multiple names: authors list (link)
  150. ↑ Mayo Foundation for Medical Education and Research (March 14, 2015). "Pneumonia" (in english). สืบค้นเมื่อ February 13, 2016.CS1 maint: unrecognized language (link)
  151. ↑ R.P. Young, R.J. Hopkins (2013). "Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities". Expert Rev Respir Med (in english). 7 (5): 533-44. doi:10.1586/17476348.2013.838018. PMID 24138695. สืบค้นเมื่อ February 13, 2016.CS1 maint: unrecognized language (link)
  152. 1 2 V. Chopra, M.A. Rogers, M. Buist, S. Govindan; และคณะ (2012). "Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis". Am J Med (in english). 125 (11): 1111-23. doi:10.1016/j.amjmed.2012.04.011. PMID 22835463. สืบค้นเมื่อ February 13, 2016. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link) CS1 maint: unrecognized language (link)
  153. ↑ Maciej Banach, Krzysztof J. Filipiak, Grzegorz Opolski (2013). Aktualny stan wiedzy na temat statyn (in polish). Poznań, Poland. p. 387. ISBN 9788363622213. |access-date= requires |url= (help)CS1 maint: multiple names: authors list (link) CS1 maint: unrecognized language (link)
  154. ↑ M.L. Vandermeer, A.R. Thomas, L. Kamimoto, A. Reingold; และคณะ (2012). "Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study". J Infect Dis (in english). 205 (1): 13-9. doi:10.1093/infdis/jir695. PMID 22170954. สืบค้นเมื่อ February 13, 2016. Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link) CS1 maint: unrecognized language (link)